Journal of cardiovascular development and diseaseOct 26, 2026

Changes in Heart Metabolism Related to Obesity and Fat Around the Heart in Atrial Fibrillation with New Diabetes Drugs and Catheter Treatment

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Oct 27, 2026

Abstract

Obesity, insulin resistance, and hypertension are associated with atrial fibrillation as part of a broader cardiometabolic disease.

Atrial fibrillation may reflect systemic metabolic dysfunction rather than solely originating from pulmonary-vein triggers.
Epicardial adipose tissue, especially near the left atrium, may link metabolic issues to atrial heart muscle changes through various biological pathways.
Lifestyle changes, such as weight loss and improved fitness, could reduce the burden of atrial fibrillation and enhance rhythm control outcomes.
Incretin-based treatments like semaglutide and tirzepatide have shown potential for significant weight loss and improvements in heart health, with some evidence suggesting lower rates of atrial fibrillation.
Evidence for reduced recurrence of atrial fibrillation after ablation remains largely observational and may be influenced by confounding factors.
The integration of various therapeutic strategies, including catheter ablation and metabolic management, could provide complementary benefits for patients.

Simplified

Atrial fibrillation (AF) is increasingly understood as the electrical expression of a systemic and atrial cardiometabolic disease rather than an isolated disorder of pulmonary-vein triggers. Obesity, insulin resistance, hypertension, sleep-disordered breathing, heart failure with preserved ejection fraction, and visceral adiposity promote atrial stretch, inflammation, fibrosis, autonomic imbalance, and conduction heterogeneity. Epicardial adipose tissue (EAT), particularly the peri-left-atrial depot, may provide a local mechanistic bridge between systemic metabolic dysfunction and atrial cardiomyopathy through paracrine, inflammatory, fibrotic, and infiltrative pathways. This framework has direct therapeutic implications. Structured weight loss, cardiorespiratory fitness, alcohol reduction, and comprehensive risk-factor management can reduce AF burden and improve rhythm-control outcomes, although the magnitude of benefit varies across populations and trial designs. Incretin-based therapies have introduced a potentially important pharmacologic route to substrate modification. Semaglutide and tirzepatide produce substantial weight loss and favorable cardiovascular and heart-failure effects, while emerging observational and prospective data suggest lower AF incidence and post-ablation recurrence. However, evidence for reduced post-ablation recurrence remains predominantly non-randomized and is susceptible to residual confounding, treatment-selection effects, and healthy-user bias. Causality, weight-independent antiarrhythmic effects, optimal timing relative to ablation, and durability after treatment withdrawal remain unresolved. Observational sodium-glucose cotransporter-2 (SGLT2) inhibitor data support further investigation of cardiometabolic approaches to rhythm control, although randomized evidence has not consistently demonstrated benefit. Our review integrates mechanistic, imaging, lifestyle, pharmacologic, and electrophysiological evidence and proposes a practical model in which catheter ablation and cardiometabolic substrate modification are complementary strategies.

Full Text

Full text is available at the source.

View Full Text ↗

Changes in Heart Metabolism Related to Obesity and Fat Around the Heart in Atrial Fibrillation with New Diabetes Drugs and Catheter Treatment

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief